Arena Pharma: Slow Belviq Launch but No Matter for Bel-Phen Data Coming

SAN DIEGO ( TheStreet) -- A slow launch for the weight-loss pill Belviq was somewhat expected, so before getting into details of sales reported Thursday, let's first talk about the "new" new Arena Pharmaceuticals ( ARNA) bull thesis: Bel-Phen.

Arena and its partner Eisai announced plans to conduct a 12-week pilot study combining Belviq with phentermine, a currently approved weight-loss medicine. Details about the design of the study were not disclosed, although patient enrollment is expected to begin late this year or early in 2014, Arena said.

Given 12 weeks of treatment, a rough guess would be top-line results announced in the second half of 2014. This catalyst now becomes the bright and shiny object of hope for Arena supporters.

They believe Bel-Phen will be the next Fen-Phen weight-loss blockbuster therapy -- minus the pesky problem of melting heart valves, of course. Belviq (lorcaserin) is chemically similar to fenfluramine, except the former is not supposed to cause the serious heart defects which caused the latter to be yanked off the market.

Whether or not Bel-Phen will be found to be heart safe remains to be seen.

Arena shares are trading down just 1% to $6.88 Thursday morning, which I attribute to the announcement of the first Bel-Phen study and little surprise about the slow Belviq launch given close tracking of weekly prescription data.

Arena reported $1.3 million in Belviq net product sales in the second quarter, which is 31.5 percent of the $4.1 million in net product sales recorded by Eisai.

Belviq hit pharmacy shelves in the beginning of June, so we're only talking about a month of sales in the second quarter. Still, $4.1 million in net product sales is light, especially considering that number includes inventory stocking.

Belviq's reported net sales underwhelmed, in part, because Eisai is giving away tons of free samples. It's estimated that between 60-70 percent of all Belviq prescriptions filled are gratis.

Separately, Eisai reported $10 million in gross sales of Belviq, which means the gross-to-net discount was a whopping 60 percent.

If you liked this article you might like

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

These Stocks Have Changed Direction

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says